Pharmacological studies in volunteers have shown that a single dose of cinnarizine enhances blood flow, steepness of the slope of the pulse wave and reactive hypernmia in both the thumb and leg (Verhaegen et al. 1974 . Increased blood flow and potentiated reactive hypernmia also occur in the more impaired lower limb circulation of patients suffering from intermittent claudication. This suggests that no untoward steal effect occurs (Verhaegen et al. 1974) . The therapeutic effects of cinnarizine in patients with circulatory disturbances have repeatedly been described (Alexander 1970 , Caesar 1971 , Schuermans et al. 1971 , Ellis et al. 1975 . The purpose of the present study was to evaluate the possible therapeutic usefulness of cinnarizine in ambulatory patients by comparing its activity with a placebo in similar conditions using a double-blind study design.
PATIENTS AND METHODS

Patients
Fifty-seven patients were included in the trial. Sex, age and weight of the patients are summarized in Table 1 . Almost two-thirds had been treated before with other drugs but with satisfactory results in less than one-third of them. Other cardiovascular disorders were also present in 10 patients; 8 others had diabetes and 13 others showed a variety of non-vascular conditions.
Experimental Design and Medication
In those patients who were already being treated for their condition with another drug, the latter treatment was stopped and a wash-out period of 1 month was observed before starting the doubleblind treatment. During this phase patients received a single, twice-daily tablet containing 15 mg of phenobarbital as an 'active placebo' since cinnarizine itself sometimes produces slight drowsiness as a side effect. Previously untreated patients were moved directly into the double-blind treatment.
During this double-blind study, patients were randomly treated with 1 capsule twice daily containing either the placebo (15 mg of phenobarbital) or cinnarizine (100 mg). The two types *In collaboration with eight Belgian general practitioners. of capsules were identical in appearance and individually packed in amounts sufficient for a 4-month treatment. The admission number of the patients indicated the type of medication to be used. The double-blind treatment lasted for 4 months. Other vasoactive drugs were prohibited for the entire trial period, but medication already in use for other conditions was maintained at the same dose level. Assessments A questionnaire about peripheral symptoms was completed at the start and after each treatment month ( Table 2) . Each item of the rating scale was scored using one of five possibilities (0= absent; 1 =mild; 2=moderate; 3 =severe and 4=extremely severe). Patients with intermittent claudication also had to assess their claudication distance (in metres) at the start and at the end of the treatment. Every month patients reported any adverse effects experienced. At the end of the study the overall result of treatment was scored by the investigator as excellent, good, doubtful or ineffective.
Results
On breaking the double-blind code it was clear that the two treatment groups were comparable (P>0.05, two-tailed probability) with regard to age, weight (Mann-Whitney U-test), sex, symptoms, previous medication, concomitant diseases and drop-outs during the study (Fisher test).
Overall Assessment ofTreatment ( patients. The difference was highly significant (P<0.001).
Questionnaire Findings
Cinnarizine was found to be superior to the placebo in the majority of the items studied Increased 5-10 x 31.2 0 Increased > lOx 6.3 0 (Table 3) . The most striking changes were in intermittent claudication, muscular cramps, cold extremities and vascular spasms. The beneficial effects observed during the 4-month treatment period are illustrated in Fig. 1 .
Walking Distance in Claudicants
The walking distance at least doubled in 75.0% of the cinnarizine-treated patients, but only in 30.0% of the controls The difference was highly significant (P<0.05, Table 4 ).
Adverse Effects
No adverse effects could be related to cinnarizine therapy. Indeed, fewer side effects were observed in the cinnarizine group than in the placebo group (Table 5) .
Conclusion
These experiments have confirmed the therapeutic benefit of cinnarizine maintenance treatment in peripheral circulatory disturbances. As shown by this double-blind evaluation, such patients demonstrate a placebo effect but cinnarizine is clearly superior to the placebo in producing amelioration.
Summary
Cinnarizine (100 mg twice daily) was studied for its effects on the symptoms of peripheral circulatory disorders. In 57 patients cinnarizine was compared double-blind to 15 mg of phenobarbital twice daily as placebo for a period of 4 months. Any other vasoactive compounds were prohibited before and during the trial. Good to excellent overall results were observed in 78.6% of cinnarizine and 14% of placebo patients. There were fewer adverse effects observed in the cinnarizine group than in those on placebo. 
